Panyod Suraphan, Wu Wei-Kai, Chen Chieh-Chang, Wu Ming-Shiang, Ho Chi-Tang, Sheen Lee-Yan
Institute of Food Science and Technology, National Taiwan University, Taipei, Taiwan.
Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
J Tradit Complement Med. 2021 Sep 22;13(2):107-118. doi: 10.1016/j.jtcme.2021.09.006. eCollection 2023 Mar.
Dietary nutrients are associated with the development of cardiovascular disease (CVD) both through traditional pathways (inducing hyperlipidemia and chronic inflammation) and through the emergence of a metaorganism-pathogenesis pathway (through the gut microbiota, its metabolites, and host). Several molecules from food play an important role as CVD risk-factor precursors either themselves or through the metabolism of the gut microbiome. Animal-based dietary proteins are the primary source of CVD risk-factor precursors; however, some plants also possess these precursors, though at relatively low levels compared with animal-source food products. Various medications have been developed to treat CVD through the gut-microbiota-circulation axis, and they exhibit potent effects in CVD treatment. Nevertheless, such medicines are still being improved, and there are many research gaps that need to be addressed. Furthermore, some medications have unpleasant or adverse effects. Numerous foods and herbs impart beneficial effects upon health and disease. In the past decade, many studies have focused on treating and preventing CVD by modulating the gut microbiota and their metabolites. This review provides an overview of the available information, summarizes current research related to the gut-microbiota-heart axis, enumerates the foods and herbs that are CVD-risk precursors, and illustrates how metabolites become CVD risk factors through the metabolism of gut microbiota. Moreover, we present perspectives on the application of foods and herbs-including prebiotics, probiotics, synbiotics, postbiotics, and antibiotic-like substances-as CVD prevention agents to modulate gut microbiota by inhibiting gut-derived CVD risk factors.
Cardiovascular disease, gut microbiota, herbal medicine, preventive medicine, dietary therapy, nutrition supplements.
膳食营养素通过传统途径(引发高脂血症和慢性炎症)以及通过元生物体发病机制途径(通过肠道微生物群、其代谢产物和宿主)与心血管疾病(CVD)的发生相关。食物中的几种分子本身或通过肠道微生物群的代谢,作为心血管疾病风险因素前体发挥重要作用。动物性膳食蛋白质是心血管疾病风险因素前体的主要来源;然而,一些植物也含有这些前体,尽管与动物源食品相比含量相对较低。已经开发出各种药物通过肠道微生物群-循环轴来治疗心血管疾病,并且它们在心血管疾病治疗中表现出显著效果。尽管如此,这类药物仍在不断改进,并且存在许多需要解决的研究空白。此外,一些药物有不良或有害作用。许多食物和草药对健康和疾病有有益影响。在过去十年中,许多研究集中在通过调节肠道微生物群及其代谢产物来治疗和预防心血管疾病。本综述提供了现有信息的概述,总结了与肠道微生物群-心脏轴相关的当前研究,列举了作为心血管疾病风险前体的食物和草药,并说明了代谢产物如何通过肠道微生物群的代谢成为心血管疾病风险因素。此外,我们阐述了食物和草药(包括益生元、益生菌、合生元、后生元以及类抗生素物质)作为心血管疾病预防剂通过抑制源自肠道的心血管疾病风险因素来调节肠道微生物群的应用前景。
Evise分类法:心血管疾病、肠道微生物群、草药医学、预防医学、饮食疗法、营养补充剂